This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study aims to assess the efficacy, safety, and PK characteristics of DA-302168S tablets in Chinese T2DM participants, and to provide dose-selection evidence for the Phase III confirmatory trial.
Age 18 to 75 years (inclusive), both sexes.
Diagnosed with T2DM according to the Chinese Diabetes Prevention and Treatment Guidelines (2024 Edition) for at least 3 months at screening, and meeting one of the following: (1) on stable metformin monotherapy for ≥8 weeks prior to screening, with a daily dose of ≥1500 mg/day or maximum tolerated dose ≥1000 mg/day, in addition to diet and exercise; stable treatment defined as no change in daily dose; (2) glycemic control by diet and exercise alone for ≥8 weeks prior to screening.
HbA1c (local laboratory) ≥7.5% and ≤11.0% at screening; and HbA1c (central laboratory) ≥7.5% and ≤10.5% at randomization.
BMI 22.5-40 kg/m² (inclusive), and stable body weight for 3 months prior to screening (weight change <5%, calculated as [max weight - min weight] / max weight × 100%).
History of type 1 diabetes, diabetes due to pancreatic injury, or other types of diabetes (excluding gestational diabetes) other than T2DM.
Acute diabetic complications (e.g., diabetic ketoacidosis, lactic acidosis, or hyperosmolar nonketotic coma) within 6 months prior to ICF signing; history of grade 3 hypoglycemia within 6 months prior to ICF signing, or ≥3 episodes of hypoglycemia (blood glucose <3.9 mmol/L) from 1 month before screening to randomization.
Clinically significant active infection or other diseases (including but not limited to neurological, psychiatric, cardiovascular, endocrine, digestive, respiratory, urinary, hematological, or immunological disorders, except those related to T2DM) within 6 months prior to screening that, in the investigator's judgment, may interfere with trial results or pose additional risks with study drug administration.
Endocrine diseases or history that may significantly affect body weight (e.g., Cushing's syndrome, obesity due to pituitary or hypothalamic disorders), or obesity due to monogenic mutations or genetic obesity syndromes.
Parallel
DA-302168S
DrugA small molecule GLP-1R agonist tablet, orally administration, once daily，16weeks.
Placebo of DA-302168S
DrugMatching placebo tablet will be provided
Change from baseline in HbA1c
measured in %
Percentage of participants with HbA1c <7.0% and ≤6.5%
percentage-point
Change from baseline in fasting blood glucose
Change from baseline in fasting lipid profile
Change from baseline in systolic and diastolic blood pressure
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
